en.Wedoany.com Reported - Oncology AI company Triomics has announced a $22 million Series B funding round, led by Battery Ventures, with participation from existing investors Nexus Venture Partners, Lightspeed, Y Combinator, and strategic investors Oncology Ventures and Precision Health Informatics, a division of Texas Oncology. This brings Triomics' total funding to over $36 million.
The new capital will be used to accelerate deployment within health systems, oncology networks, and life science organizations, expand AI, engineering, and frontline teams, and advance the development of AI agents for clinical care and research. Triomics has partnered with institutions including Memorial Sloan Kettering Cancer Center (MSK), MD Anderson Cancer Center, Yale Cancer Center and its affiliate Smilow Cancer Hospital, Mount Sinai Tisch Cancer Center, and Texas Oncology, one of the largest community oncology clinics in the U.S.
Sarim Khan, co-founder and CEO of Triomics, stated that traditional systems were never designed to handle the current information burden in oncology, which can hinder better treatment outcomes. Physicians, research coordinators, and medical assistants face case documentation that is too large and dynamic to manage manually. The company built its platform to transform complexity into actionable intelligence within workflows, and this funding will help bring this infrastructure to more cancer centers. Beyond provider workflows, Triomics has established a broader oncology network to assist life science organizations with critical clinical trial operations. The company believes that deep provider workflow integration across cancer centers, combined with oncology-specific AI infrastructure, will lay the foundation for next-generation care and research applications.
Hrituraj Singh, co-founder and CTO of Triomics, noted that oncology is the most challenging field for AI development, but also the most important. Enabling models to reliably reason across thousands of pages of medical records, pathology reports, imaging data, and evolving trial criteria, while demonstrating that reasoning process, is what distinguishes a demo product from software used in clinical practice. Since its founding in 2021 by Khan and Singh, the company has spent four years building this foundational platform. The platform uses AI agents to read complete longitudinal patient records, converting unstructured information into structured and interpretable outputs that are directly transmitted into clinical and operational workflows. Unlike lightweight summarization tools, each output is traceable and verifiable within clinical workflows. The platform supports proactive clinical trial matching, pre-visit medical record review and preparation, and oncology data abstraction for registry, quality improvement, and operational scenarios.
Published results show that users of the platform have improved trial matching rates by 40%, increased clinical trial enrollment by over 30%, and reduced medical record review time by 67%. The platform has been peer-reviewed and validated by Nature Digital Medicine and presented at ASCO conferences. Dr. Lee Schwamm, Chief Digital Health Officer at Yale New Haven Health System and Vice Chair of Digital Strategy and Transformation at Yale School of Medicine, stated that the institution is collaborating with Triomics to explore AI-based cancer registry data abstraction and reporting methods to enhance the efficiency of human registrars and meet mandatory state, federal, and professional society reporting requirements. Brandon Gleklen, a partner at Battery Ventures, said that Triomics has built the AI infrastructure needed for oncology, capable of processing complete patient records, is live at top cancer centers, and has demonstrated measurable results, including faster enrollment and reduced manual chart review, with the same infrastructure supporting multiple workflows without requiring repeated integration.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
